New antibody aims to neutralize allergies by clearing IgE
NCT ID NCT07701954
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental antibody drug called LCA-0061, designed to target and remove immunoglobulin E (IgE), a key driver of allergic reactions. The study first evaluates safety and tolerability in healthy people with elevated IgE levels, then in people with peanut allergy. Researchers are looking at how the drug moves through the body and whether it triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an antibody-based drug called LCA-0061 that targets and clears immunoglobulin E (IgE)
- What this could lead to
- If successful, this could lead to a new treatment for peanut allergy and other allergic conditions by lowering IgE levels.
- What could go wrong
- This is an early Phase 1 trial focused on safety, so it is too soon to know if the drug will effectively treat allergies. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CAN001
RECRUITINGMississauga, Ontario, L4W 1N2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.